Article

The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemia

2024-08-18

Abstract excerpt

<title>Abstract</title> <p>Second-generation tyrosine kinase inhibitors (2GTKIs) have not improved overall survival compared to imatinib due to an increase in cardiovascular events (CVEs) and deaths unrelated to chronic myeloid leukemia (CML). We retrospectively analyzed the incidence of CVEs among CML patients treated with TKIs at our institution and analyzed the risk factors for CVEs. Method and results: Fifty-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 30c4caff-03ac-52e0-9699-2ecc3bf2b68b
DOI: 10.21203/rs.3.rs-4734401/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemiaDOI 10.21203/rs.3.rs-4734401/v1Read

Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patientsSemantic proximity Read

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular ManagementSemantic proximity Read

CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter StudySemantic proximity Read

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.Semantic proximity Read

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia GroupSemantic proximity Read

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.Semantic proximity Read

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Semantic proximity Read

Ponatinib reduces viability, migration, and functionality of human endothelial cells.Semantic proximity Read

Where exactly does ponatinib fit in chronic myelogenous leukemia?Semantic proximity Read

A Narrative Review on Adverse Effects of Dasatinib With a Focus on Pharmacotherapy of Dasatinib-Induced Pulmonary ToxicitiesSemantic proximity Read

Aspirin reduces Ponatinib-induced cardiovascular toxic phenotypes and death in zebrafish.Semantic proximity Read

Ruscogenin Alleviates Intestinal Bleeding and Blood Flow Induced by Dasatinib through ROCK/MLC PathwaySemantic proximity Read